Literature DB >> 17599713

Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?

Dominik S Meier1, Howard L Weiner, Charles R G Guttmann.   

Abstract

This article discusses and reviews advanced forms of serial morphometry in the context of a disease progression model in multiple sclerosis (MS). This model of disease activity distinguishes between overall disease activity and the proportion thereof that becomes permanent damage. This translates into a progression model that features a repair potential, which, when exhausted, marks the conversion or progression from relapsing to progressive disease. The level of repair capacity at a given time determines the rate of progression. Both clinical and MRI variables appear to be in support of such a model. We examine possible MRI markers for this repair capacity, particularly the short-term behavior of new MRI lesions, quantified by methods of time-series analysis--that is, capturing lesion dynamics in the form of MRI intensity change directly, rather than shape or volume change. Lower rates of individual lesion recovery may represent lower repair and greater proximity to a progressive stage. Individuals with low transient lesion turnover appear to undergo more rapid progression and atrophy. Because disease-modifying therapies aim to alter the pathophysiological chain of inflammation, demyelination, and axonal loss, a therapeutic effect may therefore be more readily apparent as a change in lesion dynamics and recovery rate and level, rather than a change in total lesion burden or enhancing lesion number.

Entities:  

Mesh:

Year:  2007        PMID: 17599713     DOI: 10.1016/j.nurt.2007.05.008

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  50 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

2.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

3.  A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

4.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

Review 5.  Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.

Authors:  M Filippi; M A Horsfield; P S Tofts; F Barkhof; A J Thompson; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

6.  Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

Authors:  M Filippi; M Rovaris; M A Rocca; M P Sormani; J S Wolinsky; G Comi
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

7.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Authors:  L Kappos; A Traboulsee; C Constantinescu; J-P Erälinna; F Forrestal; P Jongen; J Pollard; M Sandberg-Wollheim; C Sindic; B Stubinski; B Uitdehaag; D Li
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

8.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

9.  Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.

Authors:  M A Lee; S Smith; J Palace; P M Matthews
Journal:  Brain       Date:  1998-11       Impact factor: 13.501

10.  Multiple sclerosis: a serial study using MRI in relapsing patients.

Authors:  C Isaac; D K Li; M Genton; C Jardine; E Grochowski; M Palmer; L F Kastrukoff; J Oger; D W Paty
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

View more
  18 in total

1.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Removing inter-subject technical variability in magnetic resonance imaging studies.

Authors:  Jean-Philippe Fortin; Elizabeth M Sweeney; John Muschelli; Ciprian M Crainiceanu; Russell T Shinohara
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

5.  Magnetic resonance imaging of cells in experimental disease models.

Authors:  Naser Muja; Jeff W M Bulte
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2009-07       Impact factor: 9.795

Review 6.  Magnetic Resonance Imaging in Multiple Sclerosis.

Authors:  Christopher C Hemond; Rohit Bakshi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

7.  Seasonal prevalence of MS disease activity.

Authors:  D S Meier; K E Balashov; B Healy; H L Weiner; C R G Guttmann
Journal:  Neurology       Date:  2010-08-31       Impact factor: 9.910

8.  Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis.

Authors:  Y Duan; P G Hildenbrand; M P Sampat; D F Tate; I Csapo; B Moraal; R Bakshi; F Barkhof; D S Meier; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2008-02       Impact factor: 3.825

9.  Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.

Authors:  Justin C Earp; Debra C Dubois; Diana S Molano; Nancy A Pyszczynski; Craig E Keller; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2008-04-30       Impact factor: 4.030

Review 10.  Clinical correlates of grey matter pathology in multiple sclerosis.

Authors:  Dana Horakova; Tomas Kalincik; Jana Blahova Dusankova; Ondrej Dolezal
Journal:  BMC Neurol       Date:  2012-03-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.